[CTRV] ContraVir Pharmaceuticals Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 34.81 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.35 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CTRV

Refresh chart

Strongest Trends Summary For CTRV

CTRV is in the medium-term down -72% in 1 year. In the long-term down -83% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding32.23 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV4.42 Price/Cash Per Share
Price/Free Cash Flow-25.24 ROA-48.33% ROE-58.23% ROI
Current Ratio5.79 Quick Ratio Long Term Debt/Equity Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities12.5 M Cash From Investing Activities-80 K Cash From Operating Activities-5.33 M Gross Profit
Net Profit-4.4 M Operating Profit-4.4 M Total Assets9.5 M Total Current Assets9.36 M
Total Current Liabilities1.62 M Total Debt Total Liabilities1.62 M Total Revenue
Technical Data
High 52 week2.92 Low 52 week0.34 Last close0.48 Last change-7.66%
RSI36.66 Average true range0.06 Beta1.21 Volume797.1 K
Simple moving average 20 days-8.98% Simple moving average 50 days-14.72% Simple moving average 200 days-62.91%
Performance Data
Performance Week-10.25% Performance Month-14.67% Performance Quart-29.78% Performance Half-76.21%
Performance Year-2.04% Performance Year-to-date33.33% Volatility daily5.93% Volatility weekly13.26%
Volatility monthly27.18% Volatility yearly94.17% Relative Volume435.32% Average Volume353.61 K
New High New Low

News

2019-03-04 14:01:00 | ContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference

2019-01-16 08:24:33 | The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

2019-01-15 18:25:00 | ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

2018-11-27 16:30:00 | ContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit

2018-11-06 08:00:00 | ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver Diseases

2018-10-30 08:05:00 | Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors

2018-10-30 08:00:00 | ContraVir Pharmaceuticals Completes Final Cohort Dosing in CRV431 Drug-Drug Interaction Study

2018-10-15 08:01:00 | Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team

2018-10-03 08:00:00 | Robert Foster Appointed Acting Chief Executive Officer of ContraVir Pharmaceuticals, Inc.

2018-09-18 09:00:00 | ContraVir Pharmaceuticals Announces Completion of Phase 1 with CRV431

2018-08-30 09:00:00 | ContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

2018-08-07 09:00:00 | ContraVir Pharmaceuticals Completes Data Analysis of Second Cohort in Part 1 of the Phase 1/2a Study of CRV431

2018-08-06 15:30:00 | ContraVir Pharmaceuticals Provides an Update to Corporate Objectives

2018-07-24 08:15:47 | ContraVir Stock Rose on Clinical Trial Progress Report

2018-07-23 08:00:00 | ContraVir Pharmaceuticals Reports Progress in Phase 1/2A Trial of CRV431

2018-07-10 08:35:00 | Live Investor Conference & Webinar: NASDAQ and OTC companies to present live on July 12th

2018-07-05 08:35:00 | ContraVir Pharmaceuticals to Present at Virtual Investor Conference

2018-06-29 08:00:00 | ContraVir Pharmaceuticals Announces $10.8 Million in Expected Gross Proceeds from Recently Expired Rights Offering

2018-06-25 08:00:00 | ContraVir Pharmaceuticals Initiates Dosing of CRV431 in First In-Human Trial

2018-06-21 08:00:00 | ContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL™

2018-06-20 12:30:00 | ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

2018-06-18 16:01:00 | ContraVir Pharmaceuticals to Provide Corporate, Business and Clinical Updates

2018-06-14 08:23:26 | ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States

2018-06-12 12:17:03 | ContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record

2018-06-05 09:00:00 | ContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

2018-05-31 08:00:00 | ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Liver Fibrosis in a Preclinical Model

2018-05-30 08:00:00 | ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study

2018-05-29 06:00:00 | ContraVir Pharmaceuticals to Present at 2018 BIO International Convention

2018-05-24 16:01:00 | ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split

2018-04-12 12:46:37 | ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress™

2018-04-09 06:00:00 | ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board

2018-04-03 06:00:00 | ContraVir Pharmaceuticals to Present Three Posters at the 53rd Annual International Liver Congress™

2018-02-22 08:00:00 | ContraVir Pharmaceuticals Announces TXL™ Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population

2018-02-21 16:30:00 | ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until March 9, 2018

2018-02-12 08:27:45 | Benzinga Pro's 5 Stocks To Watch

2018-02-12 06:00:00 | ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL™ Leveraging the 505b2 Regulatory Pathway

2018-02-09 06:00:00 | ContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference

2018-02-06 06:00:00 | ContraVir Pharmaceuticals Completes Renal Impairment Study with TXL™

2018-02-05 07:00:00 | ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Determination

2018-01-23 06:00:00 | ContraVir Pharmaceuticals to Present at NobleCon14

2018-01-02 06:00:00 | ContraVir Pharmaceuticals to Present at Biotech Showcase 2018

2017-12-29 16:00:00 | ContraVir Pharmaceuticals Announces John Sullivan-Bolyai, M.D., MPH Steps Down as Chief Medical Officer

2017-12-13 16:00:00 | ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21, 2017

2017-12-04 16:30:12 | Is ContraVir Pharmaceuticals Inc CTRV Undervalued?

2017-11-27 06:00:00 | ContraVir Pharmaceuticals to Make Three Presentations at HEP DART 2017

2017-11-06 06:00:00 | ContraVir Pharmaceuticals to Receive Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer NOL Program

2017-10-24 06:00:00 | ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431

2017-10-19 06:00:00 | ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL™

2017-10-17 06:00:00 | ContraVir Pharmaceuticals Announces Research Collaboration Agreement with Li Ka Shing Institute of Virology

2017-10-12 06:00:00 | ContraVir Pharmaceuticals to Present Three Posters at AASLD 2017 and Participate in the Search for HBV / HDV Cure Analyst Day